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Abstract Epithelial mesenchymal transition (EMT) is a pro-
cess by which epithelial cells acquire mesenchymal proper-
ties, generating metastases. Transforming growth factor beta
(TGF-β) is associated with this malignancy by having the
ability to induce EMT. Metformin, has been shown to inhibit
EMT in breast cancer cells. Based on this evidence we hy-
pothesize that treatment with metformin and the silencing of
TGF-β, inhibits the EMT in cancer cells. Canine metastatic
mammary tumor cell line CF41 was stably transduced with a
shRNA-lentivirus, reducing expression level of TGF-β1. This
was combined with metformin treatment, to look at effects on
cell migration and the expression of EMTmarkers. For in vivo
study, unmodified or TGF-β1sh cells were injected in the
inguinal region of nude athymic female mice followed by
metformin treatment. The mice’s lungs were collected and
metastatic nodules were subsequently assessed for EMT
markers expression. The migration rate was lower in
TGF-β1sh cells and when combined with metformin treat-
ment. Metformin treatment reduced N-cadherin and increased
E-cadherin expression in both CF41 and TGF-β1sh cells.Was
demonstrated that metformin treatment reduced the number of
lung metastases in animals bearing TGF-β1sh tumors. This
paralleled a decreased N-cadherin and vimentin expression,
and increased E-cadherin and claudin-7 expression in lung
metastases. This study confirms the benefits of TGF-β1 si-
lencing in addition to metformin as potential therapeutic
agents for breast cancer patients, by blocking EMT process.
To the best of our knowledge, we are the first to report met-
formin treatment in cells with TGF-β1 silencing and their
effect on EMT.
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Introduction
The high mortality rate in breast cancer is mainly due to meta-
static disease. The mechanisms for the occurrence of metastases
are variable and require several stages starting with the loss of
contact with neighboring cells, following the penetration of the
vessel walls, joining the new location and angiogenesis [1].
The migration and invasiveness of epithelial tumor cells
has been linked to the re-activation of a developmental pro-
cess called epithelial-mesenchymal transition (EMT) [2],
characterized by the down-regulation of epithelial markers
such as claudin, E-cadherin and keratins, loss of apical-basal
cell polarity and cell–cell adhesion, and the up-regulation of
mesenchymal markers such as N-cadherin and vimentin, as
well as the production matrix-degrading enzymes. Altogether,
this facilitates migration and invasiveness capacity during the
process of malignant transformation, and tumor cell dissemi-
nation to surrounding tissues and distant sites [2–4]. EMTcan
be induced by extracellular matrix components and growth
factors, such as transforming growth factor beta (TGF-β)
and epidermal growth factor (EGF) [5, 6], which might coop-
erate with intrinsic transforming events (e.g., oncogenes) to
promote mesenchymal phenotypes [7].
TGF-β is involved in many physiological processes re-
sponsible for regulating cellular differentiation and prolifera-
tion, migration and apoptosis. In breast and other epithelial
cancers, TGF-β is well-documented to have a stage-
dependent dual role, by acting as a suppressor of proliferation
and/or inducer of cell death in early stages of carcinogenesis,
but promoting survival, proliferation and invasiveness/
metastasis in advanced stages [8, 9]. TGF-β is a member of
the TGF-β superfamily comprised of 33 ligands, including
bone morphogenic proteins (BMP) and activins. TGF-β itself
exists in three isoforms, TGF-β1, TGF-β2 and TGF-β3. The
signaling of these isoforms is comparable in some settings,
and the expression levels varies among different tissues [10].
TGF-β1 in particular, is the best documented to play a role in
the progression of breast cancer, promoting metastasis in
many experimental rodent models. In some of these models,
TGF-β is supplied by the a tumor cell-dependent tumor mi-
croenvironment in the lung [11, 12] and bone [11, 13].
Stem cells have been investigated for their central role in the
development of tissues and organs. Research within the last two
decades suggest that cells with stem/progenitor characteristics
also play a critical role in tumor initiation and progression [14,
15]. Evidence linking EMT to breast cancer stem cells (BCSCs)
was first reported by Mani et al. [16], who showed that the
induction of this process in mammary epithelial cells trans-
formed in vitro, generate cells with BCSCs properties.
The definition of the cellular and microenvironmental signals
that induce the EMT during the progression of breast cancer is
crucial to provide new therapeutic targets in an attempt to avoid
metastasis and/or properly manage metastatic disease ro reduce
cancer mortality. Currently, intervention tools have been
employed to block cellular signaling pathways that induce
EMTand subsequent metastasis. These include oncolytic adeno-
viruses [17], RNA interference [18, 19], and molecular-targeted
drugs, such as pharmacological signalling inhibitors [4].
Several other anti-tumor and possibly EMT-targeting ap-
proaches have been more recently identified, based on the use
of drugs initially intended to treat other conditions. One ex-
ample of these is metformin, which is used orally to reduce the
glucose concentration in the blood of patients with type 2
diabetes and metabolic syndrome, with well-established and
manageable side effects and safety profiles. Following epide-
miological findings linking the use of metforming to reduced
incidence of certain cancers, particularly of the breast [20],
this drug has been widely studied for its anti-tumor activities
[21, 22]. Among the mechanims of metformin anti-tumor ac-
tivity, the activation of AMPK (AMP-activated protein
kinase) signaling has been shown to inhibit the mTOR path-
way, and several studies showed metformin’s capacity to in-
hibit epithelial-mesenchymal transition (EMT) in human
breast cancer cells [23–26]. In support of previous finding
linking stemness to EMT [16], Hirsch et al. [27] recently dem-
onstrated that tumor stem cells have a greater sensitivity to
metformin, and according to a study by Cufí et al. [28], treat-
ment with metformin suppresses the mesenchymal phenotype
by transcriptional repression of key EMT-promoting genes,
including (ex. Zinc Finger E-Box Binding Homeobox 1
(ZEB1), TWIST1, SNAIL2/SLUG, and TGF-β.
Based on the aforementioned findings, this study addressed
the possibility that blocking TGF-β signalling input and treat-
ment with metformin in a mesenchymal metastatic breast can-
cer cell line, inhibits the occurrence of metastasis. We show
that TGF-β1 knockdown by RNA interference in mesenchy-
mal CF41 canine mammary cells potentiates the EMT- and
invasiveness-targeting effects of metformin in CF41 in vitro.
A pilot animal study suggests enhanced EMT- and metastasis-
suppressing effects by this combined approach but suggest
complex interactions between the two strategies that warrant
further invesitigation.
Material and Methods
This study was approved by the ethics committee on animal use
(CEUA) of the Faculty of Medicine of Sao Jose do Rio Preto
(FAMERP) # 3244/2012, which is developed following national
and international standards of ethics in animal experimentation.
Antibodies
Antibodies used in this study were as follows: vimentin
(#M0725) from DAKO (Carpinteria, CA, USA); N-cadherin
(#sc7939) from Santa Cruz Biotechnology (Dallas, Texas,
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USA), E-cadherin (#3195S) from Cell Signaling Technology
(Danvers, Massachusetts, USA), claudin-7 (ab27487) from
Abcam (Cambridge, UK) and Alexa-Fluor®-conjugated sec-
ondary antibodies from Life Technologies (Eugene, OR, USA).
Cell Culture
The metastatic canine mammary tumor cell line CF41 (ATCC,
Manassas, VA, USA) was cultured in 75 cm2 culture flasks
(Sarstedt, Nümbrecht, Germany) with Dulbecco’s modified
Eagle’s medium – high glucose (DMEM) (Cultilab,
Campinas, SP, Brazil) supplemented with 10% fetal bovine se-
rum (FBS) (Cultilab, Campinas, SP, Brazil), penicillin (100 IU/
mL) and streptomycin (10 mg/mL) (Sigma-Aldrich, St. Louis,
MO, USA) in a humidified incubator at 5% CO2 and 37 °C.
Cell Viability by MTT (3-(4,5-Dimethylthiazol-2-Yl)
-2,5-Diphenyltetrazolium Bromide) Assay
For MTT assay, 5 × 104 cells/well were plated in 96-well plates
in 100 μL DMEM with 2% FBS. Then cells were treated for
24 h with different concentrations (1 mM, 2 mM, 3 mM and
5 mM) of metformin (Sigma-Aldrich, St. Louis, MO, USA)
diluted in ultrapure water. Thereafter, 10 μL of MTT solution
(Vibrant MTT Cell Proliferation Assay Kit, Invitrogen - Life
Technologies, Eugene, OR, USA) were added to each well
and the plates were incubated at 37 °C for an additional 4 h.
Absorbance was measured at 540 nm by ELISA plate reader
(Thermo Fisher Scientific - Waltham, MA USA). Medium with
2% FBS was used as background and subtracted from the sam-
ples. Cell viability (%) was calculated for all groups compared
to control sample (untreated), and all treatment were performed
in triplicate. Dose-response curves were generated and IC50
values was directly calculated from the dose-response curve
using equation results of linear regression.
Construction of TGF-β1 shRNA-Lentivirus and CF41
Cells Silencing
We designed shRNA sequences [29] and ordered oligonucleo-
tides encoding shRNA for TGF-β1 gene and the GFP control
(IDT - USA). The oligonucleotides were then annealed and
cloned into the lentiviral transfer plasmid pLKO 1.puro [30].
Recombinant lentivirus were generated by Viral Vector
Laboratory at LNBio-CNPEM, specialized in the development
of experimental approaches to cancer therapy, based on the sup-
ply of inhibitory molecules to tumor cells. CF41 cells were
transduced with lentivirus and selected with 2 μg/mL of puro-
mycin (Gibco, Grand Island, NY, USA). Cells were expanded
and the knockdown of TGF-β1 was confirmed by qPCR. The
target sequences selected for TGF-β1 shRNAwere: forward, 5′-
CGG CACACT GCAAGTAGA CAT TAA CCT GAC CCA
TTAATGTCTACT TGCAGTGTGTTT TT-3′; and reverse,
5′-AAT TAA AAA CAC ACT GCA AGT AGA CAT TAA
TGG GTC AGG TTA ATG TCT ACT TGC AGT GTG -3′.
The same method was used to transduce the negative control
virus containing a shRNA against green fluorescent protein
(GFP) reporter into cells (GFPsh) to control for the impact of
the lentivirus vector into cells.
The annealed oligonucleotides (insert) were ligated to the
vector pLKO 1.puro between AgeI (New England Biolabs,
Ipswich, MA, USA) and EcoRI (New England Biolabs,
Ipswich, MA, USA) restriction sites. After transformation into
DH5-α bacteria and selection by ampicillin (Sigma-Aldrich,
St. Louis, MO, USA), clones from each insert were selected
and checked by sequencing to verify the sequences of interest.
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA)
and Plasmid Midi Kit (Qiagen, Valencia, CA, USA) was used
to extract the plasmidial DNA.
Quantitative RT-PCR
TGF-β1, N-cadherin and E-cadherin gene expression was
determined by real-time PCR (qRT-PCR), according to
Bustin et al. [31]. Total RNAwas extracted from the cultured
cells with TRIZOL reagent (Invitrogen - Life Technologies,
Eugene, OR, USA). The concentration of RNA from each
sample was determined using a NanoDrop 2000
Spectrophotometer (Thermo Fisher Scientific - Waltham,
MA, USA). Each sample of total RNA was subjected to re-
verse transcription using a High Capacity cDNA kit (Applied
Biosystems, Foster City, CA, USA).
The qRT-PCR reaction was performed by StepOne Plus
Real Time PCR System (Applied Biosystems, Foster City,
CA, USA) using inventoried TaqMan assays (Life
Te c h n o l o g i e s , E u g e n e , OR , USA ) : TGF -β 1
(Cf02623325_m1), N-cadherin (Cf02696084_m1) and E-
cadherin (Cf02624269_m1). 40S ribosomal protein S5
(RPS5) and 40S ribosomal protein S19 (RPS19) were used
as endogenos control genes to normalized the expression of
genes of interest. Primers used for amplification were: RPS5
forward: 5′- TCA CTG GTGAGAACCCCC TG -3′, reverse
5′- GCC TGA TTC ACA CGG CGT A -3′, and RPS19 for-
ward 5′- GCC TTC CTC AAA AAG TCT GGG - 3′, reverse
5′- GCT TGC TCC CTA CGATGA GAA C – 3′.
The expression level of genes of interest was determined by
relative quantification (RQ) value using the average of normal-
izing genes (ΔΔCt). The samples were tested in triplicate and
all experiments included a negative control, lacking cDNA.
Migration and Invasion Assay
The migration and invasiveness of CF41 and TGF-β1sh cells
were tested with 8 μm inserts matrigel-coated membranes in
24 well plates (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA). In the upper compartment of the chamber,
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approximately 2.5 × 104 cells/insert were added into culture
medium without serum, while 750 μL of culture medium
(with 10% FBS) was added to the lower compartment with
5 mM of metformin treatment. For negative and positive con-
trols, 0.5% and 10% FBS respectively, were used.
After 24 h, the membranes were washed, fixed in parafor-
maldehyde, permeabilized in methanol, and stained with he-
matoxylin to detect the migrated cells. The countingwas made
with an inverted optic microscope (Nikon Eclipse E200,
Melville, NY, USA) and photographed by putting the insert
over a plate containing glycerol at 50%. The migration and
invasion rate was calculated by dividing the average number
of treated cells that migrated and invaded the matrigel mem-
brane by the average of the positive control cells that did so.
N-Cadherin and E-Cadherin Immunofluorescence
Staining
Cells were fixed in 4% paraformaldehyde solution and perme-
abilized with 0.5% triton X-100 (Sigma-Aldrich). The prima-
ry antibodies N-cadherin (Santa Cruz Biotechnology) and E-
cadherin (Cell Signaling Technology) were used to assess the
expression of respective antigens, and the secondary antibody
was Alexa Fluor 488 anti-rabbit IgG (Life Technologies).
Following secondary antibody, the structures were incubated
with 4′,6-diamidino-2-phenylindole (DAPI) solution (Life
Technologies) and mounted with Prolong Gold (Life
Technologies). Nuclei and antigens were visualized with a
confocal microscope (ZEISS LSM 710, software ZEN 2010,
Thornwood, NY, USA) at 40X objective magnification.
Animal Model
Athymic nude female mice (n = 30) weighing 17.8–19.4 g
were randomly separated into groups of treatment, and kept
under pathogen-free conditions at room temperature (21 to
25 °C) on exposure to light for 12 h and 12 h in the dark.
Food and water were offered ad libitum. The mice were pur-
chased from central animal laboratory of medical school of
Sao Paulo University (FM-USP).
For primary breast tumor and lung metastasis induction,
3 × 106 viable cells were washed with PBS, resuspended in
0.1 mL of serum free RPMI 1640 medium (Gibco, Grand
Island, NY, USA), and injected into the fourth right inguinal
mammary fat pad. Mice were divided according to the follow-
ing six treatment groups (n = 5 animals/group): Group I: an-
imals that were not implanted with tumor cells and were left
untreated (negative control), Group II: animals implanted with
parental CF41 cells and untreated (positive control), Group
III: animals implanted with CF41 cells treated with metformin
alone, Group IV: animals implanted with GFPsh cells and
untreated (shRNA control), Group V: animals implanted with
TGF-β1sh cells and untreated, Group VI: animals implanted
with TGF-β1sh cells and treated with metformin.
After one week of tumor cell implantation, the animals
received metformin treatment for 4 weeks. The drug was ad-
ministered intraperitoenaly (i.p.) at a dose of 200 mg/kg per
day as previously reported [32]. Tumor volume and body
weight were measured once a week. Tumor volume was cal-
culated using the formula V = length × width2/2.
Measurement of Blood Glucose of the Experimental
Group
The measurement of blood glucose was performed to verify
the glycemic variation and the potential cytotoxicity of met-
formin in treated animals, as previously reported [32]. A drop
of blood was collected using a 26 gauge needle to venipunc-
ture of tail vein of animals, once a week throughout the treat-
ment period. Glucose levels were detected using a standard
blood glucose portable apparatus (Abbott Optium Xceed®),
with individual reagent strips for rapid determination indicat-
ing amounts in milligrams per deciliter (mg/dL).
Histopathology and Immunohistochemistry
After 4 weeks of treatment the animals were euthanized, and
perfused with PBS and 4% paraformaldehyde (Acros Organics,
New Jersey, USA). The lungs were collected, fixed in 4% para-
formaldehyde, prepared for paraffin blocks and sectioned.
Standard haematoxylin and eosin (H&E) staining was performed
to evaluate the metastases presence and immunohistochemical
(IHC) staining procedures were performed as recommended by
the suppliers of primary antibodies. The following antibodies
were used to delineate the expression of corresponding antigens:
N-cadherin (Santa Cruz Biotechnology), E-cadherin (Cell
Signaling Technology), claudin-7 (Abcam) and vimentin (Dako).
Briefly, the slides containing lung tissues were
deparaffinized, rehydrated, incubated with citrate buffer at
96 °C for 30min and blocked with 0.1% of hydrogen peroxide
and 1% of BSA for 20 min each. Following this process,
sections were incubated with the primary antibody (anti-N-
cadherin, anti-E-cadherin, claudin-7 and vimentin) at 4 °C
overnight. Of note, The vimentin antibody did not detect
mouse antigen, and was therefore used to identify metastatic
colonies in serial sections that were parallely stained for the
other antigens. This was restricted to the areas of metastatic
colonies. Then, incubated with Starr Trek Universal HRP
Detection System kit (Biocare Medical, Concord, CA, USA)
containing the secondary antibody (biotinylated anti-mouse,
−rabbit, −goat immunoglobulins), peroxidase-streptavidin
conjugates, and diaminobenzidine tetrachloride (DAB) chro-
mogenic substrate. At last, all sections were counter stained
with haematoxylin, dehydrated and cover slipped with Erv
Mount (Easypath, Sao Paulo, SP, Brazil).
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Data Analysis and Statistics
All results were submitted to descriptive analysis to determine
statistical normality. An analysis of variance (ANOVA) was
performed, followed by the Bonferroni’s test. Values of
p ≤ 0.05 were considered statistically significant. The
GraphPadPrism 5 software (GraphPad Software, Inc., San
Diego, CA, USA) was used.
Results
MTTAssay of Cell Viability
CF41 cell line was subjected to MTT cell viability testing,
after 24 h treatment with increasing doses of metformin. At
5mMmetformin, there was a significant 37% reduction in cell
viability (63,18 ± 2104%) compared to control group
(100,0 ± 7155%; p < 0.05; Fig. 1). In our data, the y-axis value
from the equation of the curve, it was (IC50 = 67.68%),
wherein the correspondent doses nearest was around 5 mM
(63.17%). Based on these results, the 5 mM concentration was
used for all the following studies.
Metformin and TGF-β1 shRNA Effect on Cell Migration
and Invasion
Expression of TGF-β1 was first assessed in CF41 cells by
qRT-PCR (data not shown). This was important to infere the
feasibility of using this cell line for our knockdown experi-
ments. Next, CF41 were transduced with the shRNA-lentivi-
rus, confirming TGF-β1 knockdown by qPCR. TGF-β1
mRNA levels were decreased by TGF-β1sh #2, #3 and #4,
but sequence #3 has shown the best target silencing, compared
to the others (−1149 ± 0,05634 a.u.; p = 0.0001) [for more
details see Appendix Fig. 10].
To verify whether metformin or TGF-β1sh alone or in
combination would decrease cell invasive potential, we per-
formed a transwell assay using matrigel-covered membranes
(Fig. 2). After 24 h of metformin treatment, there was a sig-
nificant decrease (49,03 ± 5227%) in invasion and migration
of CF41 ce l l s as compared to pos i t ive con t ro l
(100,0 ± 5853%; p = 0.0001). When compared to GFPsh cells
untreated (96,74 ± 2542 a.u.), there was a significant decrease
(57,85 ± 5394%; p = 0.0001) in invasion and migration of
TGF-β1sh cells and of TGF-β1sh cells treated with metfor-
min (10,48 ± 1876%; p = 0.0001). For this assay, the positive
control (10% serum at the bottom well) was used as the basal
level to compare to all treatments. The negative control (2%
serum) in this assay showed a 86% reduction (13,74 ± 1195%)
in the migration/invasion of the cells compared to that of pos-
itive control (100,0 ± 5853%; p = 0.0001) (data not shown).
N-Cadherin and E-Cadherin Expression after Treatment
with Metformin and TGF-β1 shRNA
N-cadherin and E-cadherin are key EMT markers in breast
cancer [33]. Therefore, we examined the expression level of
these markers to assess possible EMT-suppressing effects of
TGF-β1 silencing and metformin treatment, alone or in
combination.
Treatment with metformin for 24 h decreased N-cadherin
gene and protein expression. Specifcally, we observed a de-
crease in N-cadherin mRNA expression in parental cells treat-
ed with metformin (−0,1947 ± 0,03820 a.u.; p = 0.008) com-
pared with positive control (0,0 ± 0,0110 a.u.), and in
TGF-β1sh cells and TGF-β1sh cells plus metformin
(−1023 ± 0,07815 a.u.; p = 0.0002) compared to GFPsh con-
trol (0.0 ± 0,2077 a.u.). The protein levels were significantly
r e du c e d by t h e s ame t r e a tmen t s (me t f o rm i n ,
1 3 , 6 2 ± 1 2 9 8 a . u . ; p = 0 . 0 0 0 1 ; TGF -β 1 s h ,
11,40 ± 0,9234 a.u.; p = 0.0001 and TGF-β1sh + metformin,
7633 ± 0,7067 a.u.; p = 0.0001), compared with respective
control groups (Control, 25,97 ± 2092 a.u.; GFPsh,
25,62 ± 1966 a.u.) (Fig. 3). E-cadherin protein expression
was higher in CF41 parental cells treated with metformin
(9683 ± 0,9668 a.u.; p = 0.0001) compared to untreated con-
trol cells (7217 ± 0,6032 a.u.) (Fig. 4). In the TGF-β1 silenc-
ing cells, E-cadherin expression was significantly higher com-
pared to GFPsh control cells (8250 ± 0,9378 a.u.) at both the
Fig. 1 Effect of metformin on viability of canine mammary tumor cell
line. CF41 cells were treated with 1 mM to 5 mM of metformin for 24 h
and cell viability was measured byMTTassay. Significance calculated by
ANOVA followed by Bonferroni’s test (± S.E.M. *p < 0.05)
Fig. 2 Cell migration and invasion. Cell migration and invasion assay
was carried out in CF41 and TGF-β1sh cells after treatment with 5 mM
metformin. Statistically significant differences, verified by ANOVA
followed by Bonferroni’s test. *p < 0.05 in comparison to control of
untreated parental cells (solid columns) and to control of shRNA-
expressing cells (dotted columns)
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protein (13,78 ± 0,9415 a.u.; p = 0.03) and RNA level.
Interestingly, when TGF-β1 silenced cells were treated with
metformin, E-cadherin expression levels (6500 ± 0,6362 a.u.;
p = 0.0001) returned to GFPsh control levels (8250 ±
0,9378 a.u.) (Fig. 4).
Effects of Metformin and TGF-β1 Silencing in Animal
Model of Breast Cancer Metastasis
To determine the impact of combined metformin and TGF-β1
shRNA intervention in metastasis, we employed a CF41
mouse xenograft model of breast cancer metastasis to the lung.
All mice remained healthy during the experiment and no clin-
ical or pathologic signs of metformin treatment were found.
All groups had weight changes, however, no changes were
significant between the treated groups and the control group
(p > 0.05) [for more details see Appendix Fig. 11]. After a
week of tumor cell implantation, all groups were assessed
weekly for blood glucose levels. The animals from the nega-
tive control group, who received no tumor induction, present-
ed the same glycemic variation that animals treated with met-
formin, and the other evaluated groups (p > 0.05) [for more
details see Appendix Fig. 12]. In addition, behavioral indica-
tors such as drowsiness or agitation were not observed.
The animals received metformin treatment from the second
week of tumor cell implantation, and the results of first week
showed that tumor growth was random in the animals of all
groups. There was a gradual growth of the primary tumor in
the breast region in all groups implanted with tumor cells after
5 weeks, except GFPsh control group, which showed an ab-
solute regression of the tumor size in all animals after the third
week of monitoring relative to first week of parental untreated
cells (p = 0.001) [for more details see Appendix Fig. 13]. As
shown in Fig. 5, animals of the group treated with metformin
has less metastasis (1000 ± 0,3162 a.u.) compared to control
group (4800 ± 0,9695 a.u.; p = 0.005). For the GFPsh control
group, although no specific gene silencing is expected in these
tumors, we noted that they displayed reduced tumor growth
[for more details see Appendix Fig. 13] and a reduced inci-
dence and number of metastasis (20% and 30%, respectively)
as compared to the untreated control (parental cells) group
(Fig. 5), although no statistically significant differences in
the number of metastasis/lung were observed (Fig. 5). It was
observed that tumor size is inverse to the number of metasta-
ses found. TGF-β1sh group treated with metformin or not it
Fig. 3 N-cadherin expression in CF41 cell line. a Photomicrographs of
immunofluorescence (IF) staining for N-cadherin (green) and Dapi (blue)
in CF41 and TGF-β1sh cells treated with metformin. ZEISS, 2014, 40X.
b Plotted results of immunofluorescence quantification. c Gene
expression of N-cadherin after treatment, compared to control of
untreated parental cells and control of shRNA-expressing cells,
respectively. Each column is the mean ± standard error of triplicates.
Significant values from ANOVA followed by Bonferroni’s test (±
S.E.M. *p < 0.05)
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Fig. 4 E-cadherin expression in CF41 cell line. a Photomicrographs of
immunofluorescence (IF) staining for E-cadherin (green) and Dapi (blue)
in CF41 and TGF-β1sh cells treated with metformin. ZEISS, 2014, 40X.
b Plotted results of immunofluorescence quantification. c Gene
expression of E-cadherin after treatment, compared to control of untreated
parental cells and control of shRNA-expressing cells, respectively. Each
column is the mean ± standard error of triplicates. Significant values from
ANOVA followed by Bonferroni’s test ((± S.E.M. *p < 0.05)
Fig. 5 Analysis of lungmetastasis in animal model. a Percentage of mice
who had metastasis in each group. b Incidence of metastases in the lungs
of mice in each group. Statistically significant differences, verified by
ANOVA followed by Bonferroni’s test. * p < 0.05 in comparison with
control of untreated parental cells and control of shRNA-expressing cells.
cMacroscopic lung metastasis. Arrows indicate sites of lung metastasis
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was observed higher primary tumor size [for more details see
Appendix Fig. 13] and less pulmonary metastass in both, the
TGF-β1sh group (1000 ± 0,3162 a.u.; p = 0.05) and
T G F - β 1 s h g r o u p t r e a t e d w i t h m e t f o r m i n
(0,6000 ± 0,2449 a.u.) compared to GFPsh control group
(3000 ± 0,8367 a.u.; p = 0.02) (Fig. 5). However, CF41 was
shown to be a highly metastatic canine mammary tumor cell
line when implanted in athymic nude mice and these animals
had smaller tumor size, compared to TGF-β1sh and
TGF-β1sh treated with metformin groups.
For analysis of protein markers associated to EMT (N-
cadherin, E-cadherin, vimentin, and claudin-7) in lung meta-
static colonies, IHC was performed, followed by densitometry
quantification.
The presence of N-cadherin was observed in lung metasta-
ses from all groups, with lesser intensity in the groups treated
with metformin and with TGF-β1sh cells. Animals implanted
with CF41 cells and treated with metformin showed a signif-
icant reduction in protein expression of N-cadherin
(106,7 ± 1307 a.u.) when compared to the control group
(154,1 ± 1817 a.u.; p = 0.0001)). The animals implanted with
TGF-β1sh cells (108,1 ± 0,8859 a.u.; p = 0.0001) and
TGF-β1sh cells plus subsequent metformin treatment
(104,8 ± 1049 a.u.; p = 0.0001) also showed a statistically
significant reduction in N-cadherin expression in the lungs
compared to GFPsh group (140,7 ± 1853 a.u.) (Fig. 6).
E-cadherin had increased expression in the lung metastatic
lesion of the animals implanted with parental cells and treated
with metformin (155,4 ± 1577 a.u.), compared to the lungs of
untreated animals (105,3 ± 1383 a.u.; p = 0.0001). A similar
effect was seenin the animals implanted with with TGF-β1sh
cells in the absence (139,0 ± 1776 a.u.; p = 0.0001) or after
metformin treatment (143,4 ± 2013 a.u.; p = 0.0001), as com-
pared to the GFPsh group (114,6 ± 1623 a.u.) (Fig. 7).
Treatment with metformin reduced vimentin expression in
lungmetastatic colonies (126,3 ± 1378 a.u.) as compared to those
formed by control, untreated parental cells (166,5 ± 1392 a.u.;
p = 0.0001). Similar results were observed for the TGF-β1sh
(118,5 ± 1408 a.u.; p = 0.0001) and TGF-β1sh plusmetformin
groups (114,0 ± 1606 a.u.; p = 0.0001), in relation to GFPsh
group (166,6 ± 1895 a.u.) (Fig. 8).
Animals treated with metformin had a statistically signifi-
cant increase in protein expression of claudin-7
(131,5 ± 1775 a.u.) compared to the positive control group
(116,3 ± 1326 a.u.; p = 0.0001). Similarly, animals transfected
with TGF-β1sh cells and treated with metformin had in-
creased protein expression relative to GFPsh control group
(131,0 ± 1786 a.u.; p = 0.008) (Fig. 9).
Fig. 6 N-cadherin protein
expression. a Semi-quantitative
analysis of N-cadherin protein
expression by densitometry in
metastatic colonies. b N-cadherin
immunostaining in the lungs.
Statistically significant
differences, verified by ANOVA
followed by Bonferroni’s test. *
p < 0.05 in comparison with
control of untreated parental cells
and control of shRNA-expressing
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Discussion
Mean metformin IC50 values obtained in our experiments was
about 5 mM, ranging from 1 to 10 mM in CF41 cells.
Metformin concentrations used in this study were selected ac-
cording to previous studies which showed that concentrations
higher than 10 mM were cytotoxic to cells from various tumor
types and that lower doses had excellent results in cell viability,
cell migration and invasion. Hirsch et al. [27] showed that met-
formin at 0.1–0.3 mM could inhibit morphological transforma-
tion and invasive growth in breast cancer cells having selective-
ly ability to kill cancer stem cells, and also higher doses as 10–
30 mM are toxic for non-transformed human mammary epithe-
lial cells (MCF-10A). Hwang and Jeong [34], determined the
effect of metformin at 5 mM on tumor invasion and migration
on fibrosarcoma cells. Cufi et al. [28] in their review showed in
MCF-7 and MDCK (canine kidney) cells treated with 1 mM
was able to decrease EMT markers and cell proliferation.
Cerezo et al. [35] also showed that metformin could dramatical-
ly impairs themelanoma tumors growth, migration and invasion
in vitro using 5 and 10 mM. Zhang et al. [36] demonstrated that
metformin at 5 mM significantly inhibited the proliferation and
TGF beta EMT induction of prostate cancer cells at 48 and 72 h.
Recently, Saeki et al. [37] demonstrated that canine mammary
gland tumors cells are sensitive at the concentrations of 2.2 mM
up to 20 mM, where in metastatic cells shows around 50% of
susceptibility to treatment at 5 mM after 24 h of metformin,
corroborating with our study. In another recent study, Barbieri
et al. [38] demonstrated that the concentration of 1 up to 10 mM
of metformin caused a significant reduction of cell viability, in a
dose-dependent manner, in canine mammary carcinoma stem
cells cultures. However, using higher concentrations (20 mM)
growth recovery was minimal after 24 h of treatment, and
completely abolished after 48 h, indicating a cytotoxic activity.
In in vivo study, the dosage of 200mg/kg ofmetformin was
defined according to the study of Rattan et al. [32] that used
A2780 ovarian cancer cells injected intraperitoneally in nude
mice and when treated with metformin in drinking water, re-
sulted in a significant reduction of tumor growth, accompa-
nied by inhibition of tumor cell proliferation as well as de-
creased live tumor size and mitotic cell count. In another
study, Kisfalvi et al. [39] observed that maximal inhibitory
effect on the increase in tumor volume (∼80%) of PANC-1
(pancreact carcinoma) tumor xenografts was achieved by ad-
ministration of metformin at 200 mg/kg.
EMT is well-documented to mediate the process of metas-
tasis, particularly in breast cancer [40]. Developing strategies
to maximize inhibiton of EMT to halt cancer progression has
high potential to translate into patient benefit. In the present
study, treatment with metformin in vitro was able to decrease
Fig. 7 E-cadherin protein
expression. a Semi-quantitative
analysis of E-cadherin protein
expression by densitometry in
metastatic colonies. b E-cadherin
immunostaining in the lungs.
Statistically significant differ-
ences, verified by ANOVA
followed by Bonferroni’s test. *
p < 0.05 in comparison with
control of untreated parental cells
and control of shRNA-expressing
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the viability of the mesenchymal/metastatic CF41 cell line, as
well as their rate of migration and invasion. Furthermore, as
expected [4], metformin reduced mesenchymal marker ex-
pression N-cadherin and increased the expression of the epi-
thelial marker E-cadherin.
There are few studies that demonstrate the action of met-
formin on EMT. In accordance with our results, Qu et al. [25]
demonstrated that metformin reversed the EMT phenotype
and decreased invasiveness of human breast cancer cell lines
MDA-MB-231 and MCF-7. Further, Cerezo et al. [35] dem-
onstrated that metformin was able to inhibit cell invasion of
melanoma cell lines, while Hwang and Jeong [34] showed
antimetastatic action of metformin in fibrosarcoma cells,
inhibiting cell migration and invasion.
Several mechanisms of antitumor action of metformin have
been described, especially a direct effect on AMPK activation,
which results in inhibition of mTOR signaling pathway [36]. It
has been demonstrated that AMPK activation inhibits EMT
induced by TGF-β in breast cancer cells [28]. Of the aforemen-
tioned, Qu et al. [25] study demonstrated that treatment with
metformin activated AMPK signaling pathway in estrogen re-
ceptor positive (ER+) breast tumor cells that were
chemoresistant to 5-fluorouracil (MCF-7/5-FU), as well as
triple-negativeMDA-MB-231, reversing the multidrug resistant
phenotype beyond effects on the EMT process. Metformin also
targets other pathways associated with EMT, such as mTOR
signaling pathway-S6 K. The high expression of the tyrosine
kinase p70S6 K has been associated to low expression of E-
cadherin and high expression of N-cadherin and vimentin. Thus,
treatment with metformin inhibits the mTOR-S6 K pathway,
and this could also be one possible mechanism by which met-
formin inhibits EMT and metastasis [41, 42].
Several signaling pathways resulting from the activity of
different growth factors are involved in the EMT process,
especially TGF-β signalling [43]. Thus, given the importance
of TGF-β1 in the induction of EMT, and the tendency of
tumor cells to activate this pathway in an autocrine fashion
by secreting their own TGF-β, the present study focused on
gene silencing of TGF-β1 in the mesenchymal and metastatic
CF41 cell line. As expected, the in vitro results showed that
silencing of TGF-β1 inhibited cell migration and invasion,
and there was a greater reduction with the addition of metfor-
min to gene silencing, suggesting cooperativity of treatments
in most experiments. Similar to our results, Moore et al. [18],
using metastatic human mammary tumor cells, demonstrated
that TGF-β1 silencing by RNAi led to a decrease of 35% of
cell migration and 55% of cell invasion.
Analyzes of mRNA and protein expression in vitro and
in vivo studies demonstrated that silencing of TGF-β1 resulted
in reduction of the mesenchymal markers N-cadherin and
Fig. 8 Vimentin protein
expression. a Semi-quantitative
analysis of vimentin protein
expression by densitometry in
metastatic colonies. b Vimentin
immunostaining in the lungs.
Statistically significant
differences, verified by ANOVA
followed by Bonferroni’s test. *
p < 0.05 in comparison with
control of untreated parental cells
and control of shRNA-expressing
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vimentin and enhanced expression of the epithelial markers E-
cadherin and Claudin-7, and was equally or more effective in
addition to metformin. To the best of our knowledge, this is the
first study to investigate the combined action of TGF-β1 silenc-
ing and metformin treatment. Zhang et al. [36] demonstrated
that in vitro treatment with metformin inhibited EMT process
induced by TGF-β1 in human prostate cancer cells, reducing
the gene and protein expression of N-cadherin and vimentin,
and increasing the expression of E-cadherin and β- catenin.
Our in vivo study found that there were fewer mice with
lung metastases and fewer metastastic colonies/lung in ani-
mals that received cells with TGF-β1 silenced or animals that
were treated with metformin, as compared to untreated paren-
tal cells. The effect was further enhanced by combined
TGF-β1 silencing and metformin treatment, and was signifi-
cant as compared to animals implanted with shRNA control
cells. Our in vivo results with TGF-β1 silencing alone are in
agreement with a previous study by Moore et al. [18] using a
mouse xenograft model of metastatic MDA-MB-435 human
breast cancer cells, where a 90% reduction in the number of
macroscopic lung metastases was observed in the TGF-β1
shRNA group compared to the control group. Further, the
increased tumor growth by TGFβ silencing is also in agree-
ment with the previously reported dual function of this factor
in breast cancer, whereby it can simultaneously act as a
primary tumor supressor and metastasis inducer, as initially
observed in seminal studies by Dr. Massague’s [44] group.
Others studies support a model, in which TGF-β1 inhibits
the development of early, benign lesions, but when the tumor
suppressor activity is overridden by oncogenic mutations in
other pathways, promotes invasion and metastasis [43, 45,
46]. Studies suggest that expression of the TGFβ type II re-
ceptor (TβRII) in breast cancer cells prevents tumor formation
[47], while inactivatingmutations or overexpression of a dom-
inant negative form of the receptor abolish TGFβ tumor sup-
pressive effects and increase tumorigenicity [48]. Moreover,
low expression levels of TβRII are correlated with more ad-
vanced and aggressive tumor stages, suggesting that the
TGFβ signaling pathway acts as a tumor suppressor in the
early stages of tumor development [49, 50].
Relative to tumor size, there was a gradual growth of the
primary tumor in the breast region in all groups implanted with
tumor cells after 5 weeks, except GFPsh control group, which
showed an absolute regression of the tumor size in all animals
after the third week of monitoring relative to first week of pa-
rental untreated cells. Supposedly, when GFP-reporter gene was
transfected into metastatic CF41 cells, there was a selection of
these cells due transfection method and also by the use of anti-
biotics to select the transfected positive cells and this process
may have caused the survival only in resistant cells and thus
Fig. 9 Claudin-7 protein
expression. a Semi-quantitative
analysis of claudin-7 protein
expression by densitometry in
metastatic colonies. b claudin-7
immunostaining in the lungs.
Statistically significant
differences, verified by ANOVA
followed by Bonferroni’s test. *
p < 0.05 in comparison with
control of untreated parental cells
and control of shRNA-expressing
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more aggressive andmetastatic compared to the total population
of unmodified cells. This selection made these modified cells
more aggressive and more resistant, therefore, increasing the
metastatic capacity compared to unmodified cells, as a result,
decreased primary tumor size and increased metastatic sites. In
contrast, the cells which had the modification to inhibit
TGF-β1, showed greater primary tumor size due inhibit the
aggressiveness of these cells, showing also a decrease of the
migratory capacity, highlighting again the importance of the
inhibition of TGF-β1 in this type of metastatic cells.
Meanwhile, metastatic cells CF41 unmodified, had maintained
their aggressiveness, because TGF-β1 was not inhibited, thus
showing tumor growth and metastatic potential, as expected.
Relative to tumor size in vivo after treatment with metfor-
min,Wang et al. [51], demonstrated that xenograft tumor from
lung adenocarcinoma A549 cells treated with metformin
(200 mg/kg/day) was signifiantly decreased in size. The same
was observed in a study of Tsutsumi et al. [52] that showed a
tumor volume significantly decreased after treatment with
metformin compared with the control in animal xenografic
model with prostate cancer cell line LNCaP. On the other
hand, Lipner et al. [53] demonstrated that metformin does
not inhibit growth of patient-derived xenograft (PDX) tumors.
No tumor growth inhibition or regression was seen in any of
the four PDX tumor lines (Capan-2, CFPAC-1, HPAF-II, and
SW1990) at any time point measured and tumor architecture
remained grossly unchanged following 28 days of treatment
as assessed by hematoxylin and eosin staining.
Our findings with metformin treatment also support previous
results. The addition of metformin to conventional chemothera-
py was observed to inhibit tumor progression and delay relapse
in animal models of breast, prostate and lung cancer [32], and
Zhang et al. [54] observed that patients with colorectal cancer
and type 2 diabetes treated with metformin showed a signifi-
cantly reduced rate of distantmetastasis compared to the untreat-
ed group. A study of Rattan et al. [32] demonstred with A2780
ovarian cancer cells injected intraperitoneally in nude mice that
significant pulmonary metastasis was seen in the lungs of un-
treated mice but not in metformin-treated mice.
Interestingly, although we observed a significantly enhanced
in vitro effect of combined TGF-β1sh and metformin as com-
pared to each treatment alone, with relation to viability, inva-
siveness and EMT markers, the combined treatment was better
that each treatment alone at reverting EMT features. It is possi-
ble that other factors produced by the tumor stroma (including
TGF-β1 it self) also induce EMTand metformin treatment does
not have the capacity to fully inhibit this in addition to the EMT-
promoting effect of tumor cell-derived TGF-β1. In this regard,
combining metforming with a TGF-β1 blocking antibody that
targets both the cell autonomous and the stromal tumor com-
partments might be more effective at maximizing the EMT in-
hibitory effect. More importantly, this will be more feasible in
actual patients, as antibodies of this kind has already
demonstrated safety in clinical trials [55, 56]. Based on the
divergence between these and our in vitro findings, one possi-
bility is that metformin treatment in vivo promotes stroma-
dependent compensatorymechanisms that yield TGF-β1 silenc-
ing at the tumor cell compartment not only ineffective at halting,
but possibly more permissive of, lung colonization.
Alternatively, and based on recent evidence of the involvenmnet
of a mesenchymal-to-epithelial reversion in metastatic coloniza-
tion [4, 5, 57, 58], it is also possible that excessive rescuing of an
epithelial phenotype might in part promote lung colonization.
We are currently investigating these possibilities.
Conclusion
The present study proved the efficacy of metformin at signif-
icantly reducing cell viability of the mesenchymal, metastatic
CF41 cells. Either metformin treatment or TGF-β1 silencing
in CF41cells resulted in enhanced expression of epithelial
markers and decreased expression of mesenchymal markers,
as well as inhibition of invasiveness and metastases, and the
combination of the two approaches was more effective that
each treatment alone in vitro and in vivo. Our data suggests
that therapies combining TGF-β1 targeting and metformin
may be effective in reducing the process of EMTand metasta-
tic potential. Further studies are necessary to improve our
understanding of metformin’s effect on the tumor microenvi-
ronment in vivo, as to be able to design an approach that
exploits these findings more effectively.
ATCC, American type culture collection; BSA, Bovine
Serum Albumin; cDNA, Complementary DNA; TGF-β1sh,
Small hairpin RNA constructs targeting TGF-β1 in CF41
cells; DMEM, Dulbecco’s modified Eagle’s medium; EMT,
epithelial-mesenchymal transition; FBS, fetal bovine serum;
GFPsh, green fluorescent protein reporter into CF41 cells;
H&E , Haema toxy l i n and eo s i n ; MTT, 3 - ( 4 , 5 -
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
PBS, Phosphate buffered saline; qRT-PCR, Real time poly-
merase chain reaction; RNA, Ribonucleic acid; RPS5,
Ribosomal Protein S5; RPS19, Ribosomal Protein S19;
TBS-T, Tris-Buffered Saline and Tween 20; TGF-β1,
Transforming growth factor beta 1.
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Fig. 11 Body weight. Average
body weight of animals in the
different treatment groups as a
function of time. No statistically
significant differences were
observed (p > 0.05)
Fig. 10 TGF-β1 mRNA expression in cells with TGF-β1 knockdown.
Analyses of TGF-β1 mRNA expression in cells with TGF-β1
knockdown (TGF-β1sh cells) to select the best sequence to implant into
the animals. The numbers 1, 2, 3 and 4 correspond to different TGF-β1
shRNA sequences. Statistically significant differences were determined
by ANOVA followed by Bonferroni’s test. * p < 0.05 in comparison with
untreated parental cells
Fig. 12 Glycemia. Glucose
levels in the different animal
groups as a function of time. No
statistically significant differences
were observed (p > 0.05)
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